Levels of neutralizing antibodies against omigran after the third dose of the Astrogenogen Kovit-19 vaccine were as broad as those obtained after two doses against the delta variant.
AstraZeneca Covid-19 vaccine (ChAdOx1-S [recombinant]Significantly increased antibody levels against the omigran variant of SARS-CoV-2 (B.1.1.529) after the third booster dose, according to data from a new laboratory study.1
Omigron neutralization titers were improved after the third dose of the Astrogenogen Covit-19 vaccine compared with titers obtained after the second dose. Conditions observed after the third booster dose were higher than those of neutralizing antibodies previously found in individuals with COVID-19 disease. (Alpha, beta, delta and original strain types) and recovered naturally. The sera, obtained from individuals one month after receiving the third booster dose, neutralized the Omigron variant similar to that found one month after the second dose against the delta variant. Two doses of the 1Astrogeneca Govit-19 vaccine have been linked to protection against delta variation in field studies.2,3
The study examined blood samples taken from patients with Covid-19 disease, those vaccinated in the two-dose schedule and the third booster dose, and those who reported infection with other types of COVID-19. The study looked at samples from 41 people who received three doses of the Astrogenogen Covit-19.1 vaccine.
The study was conducted independently by researchers at the University of Oxford and the results were published online on the bioRxiv preprint server.
Sir John Bell, a professor of medicine at the University of Oxford (UK) and one of the researchers, said: “It is encouraging that current vaccines have the potential to protect against Omigran after the third booster dose, and especially to support the use of the third booster dose as part of national immunization strategies and to support the spread of the virus. .
Sir Mene Pangallos, Acting Vice President of AstroGeneca Biopharmaceuticals R&D, said: “The Astrogeneca Covit-19 vaccine plays a key role in immunization programs around the world, and this information helps us to understand how this vaccine can be given as a third booster dose. It is also important to look beyond antibodies to understand.As we understand Omicron well, we will find that response cells provide long-term protection against serious disease and hospitalization.
Data from another laboratory study confirm the effect of the AstraZeneca COVID-19 vaccine against Omicron. Therefore, those who were vaccinated with two doses of the vaccine retained their neutralizing activity against Omigran, although there was a decrease compared to the original strain.4 In other studies, the Astrogeneca Kovit-19 vaccine was found to be more versatile and more durable. Cell response to multiple categories. It receives a more comprehensive response than antibodies and may help protect against Covit-19. 1.5-9
In addition, the company analyzes blood samples taken from participants in the second / III test to evaluate the neutralizing activity when used as a third booster dose against the omicron for the Govit vaccine. As well as its next-generation COVID-19 vaccine candidate, AZD2816. Data from these studies are expected soon.
Data currently available against variants of anxiety, with the exception of Omicron, support the use of a third booster dose of the AstraZeneca COVID-19 vaccine according to a uniform or multifaceted schedule.6,10
At the same time, co-analysis of the COV001 and COV002 trials showed that the third dose of the astringent COVID-19 vaccine, at least six months after the second dose, increased the antibody level sixfold and maintained T cells. The third dose resulted in a more neutralizing activity against the alpha, beta and delta variants compared with the two dose regimens. In the trial, the third dose of the Astrogenogen Covit-19 vaccine was found to be less reactogenic than the first dose.6.
Similarly, the third booster dose of the AstraZeneca Covit-19 vaccine showed significantly higher immunity to COST after control over the delta variant and the control against the original strain after the sequence of the primary vaccines of AstraZeneca Covit-19 or Pfizer Bioendech. Vaccine (BNT162b2).